Cardiovascular outcomes in patients with primary aldosteronism after treatment
Cardiovascular outcomes in patients with primary aldosteronism after treatment
复制标题
DOI：
10.1001/archinternmed.2007.33
复制
发表时间：
2008-01-14
影响因子：
--
通讯作者：
Sechi, Leonardo A.
中科院分区：
文献类型：
--
作者：
Catena, Cristiana;Colussi, GianLuca;Sechi, Leonardo A.
背景：实验和人体研究表明，长期暴露于升高的醛固酮水平会导致心脏和血管损伤。方法：我们调查了原发性醛固酮增多症患者手术或内科治疗后的长期心血管结果。54名有或没有肾上腺腺瘤证据的患者在接受肾上腺切除术或螺内酯治疗后进行了前瞻性随访，平均随访时间为7.4年。将原发性醛固酮增多症患者与原发性高血压患者进行比较，并将其血压控制在140/90毫米汞柱以下。结果：在基线时，原发性醛固酮增多症患者心血管事件的发生率(35%)高于高血压患者(11%)(优势比，4.61；95%可信区间，2.38-8.95；P
Background: Experimental and human studies demonstrate that long-term exposure to elevated aldosterone levels results in cardiac and vascular damage.Methods: We investigated long-term cardiovascular outcomes in patients with primary aldosteronism after surgical or medical treatment. Fifty-four patients with or without evidence of adrenal adenomas were prospectively followed up for a mean of 7.4 years after treatment with adrenalectomy or spironolactone. Patients with primary aldosteronism were compared with patients with essential hypertension and were treated to reach a blood pressure of less than 140/90 mm Hg. The main outcome measure was a combined cardiovascular end point comprising myocardial infarction, stroke, any type of revascularization procedure, and sustained arrhythmias.Results: At baseline, the prevalence of cardiovascular events was greater in primary aldosteronism (35%) than in essential hypertension (11%) (odds ratio, 4.61; 95% confidence interval, 2.38-8.95; P